PINDOLOL (pindolol) by Viatris (2) is clinical pharmacology pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (isa) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Approved for the management of hypertension. First approved in 1992.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity.
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)
EScitalopram PIndolol ONset of Action
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
Worked on PINDOLOL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.